Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin. Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune "memory" in glioblastoma animal models
Under terms of the agreement, AbbVie and Gilgamesh Pharmaceuticals have agreed to research and develop a portfolio of next-generation therapeutics for psychiatric disorders.
Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin. Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune "memory" in glioblastoma animal models
Access to reliable testing allows for better patient management and more informed public health decisions. By utilizing OmeCare's dedicated CLIA-certified and CAP-accredited facility, Vivera and OmeCare are helping to eliminate excessive wait times.
SQI Diagnostics, Inc. CEO Mr. Robert L. Chioini stated, “Within our organ transplant, autoimmune disease, and serological testing business units we have multiple products in clinical development, and we believe these advanced tests have the potential to offer patients and consumers significant benefit once they receive regulatory approval.
Oncimmune CEO dam M Hill said: "We are pleased to announce this partnership between our ImmunoINSIGHTS business and another world-leading biopharmaceutical company."
Micron Biomedical reports their applicator-free technology is well-suited for the administration of vaccines and, in particular, for measles-rubella vaccination in low- and middle-income countries.
Vitanova Biomedical is developing a prostate-specific membrane antigen targeted drug, VNBp-1, formulated as a first line treatment for local stage prostate cancer.
The initial contract is for 8 months. Todos has also been granted a priority right to supply the lab with up to 75,000 COVID PCR tests per day in the event the laboratory sees significant additional testing demand.
By using this website you agree to accept Medical Device News Magazine Privacy Policy
